Abstract
The complete coding region of the p53 gene was sequenced from 316 consecutively presented breast cancers, of which 97 were lymph node positive and 206 were node negative. The p53 status was related to prognosis and effect of adjuvant therapy. In all, 69 individual mutations, 29 in node–positive tumours, were demonstrated throughout the whole coding sequence. The mutation sites were partly different for node–positive and node–negative patients. p53 mutations in the evolutionary conserved regions II and V were associated with significantly worse prognosis. Adjuvant systemic therapy, especially with tamoxifen, along with radiotherapy seemed to be of less value to p53 mutation– and lymph node–positive tumours.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339, 1–15, 71–85 (1992).
Levine, A.J., Momand, J. & Finlay, C.A. The p53 tumour suppressor gene. Nature 351, 453–456 (1991).
Vogelstein, B. & Kinzler, K.W. p53 function and dysfunction. Cell 70, 523–526 (1992).
Lane, D.P. p53, guardian of the genome. Nature 358, 15–16 (1992).
Frebourg, T. & Friend, SH. The importance of p53 gene alterations in human cancer: Is there more than circumstantial evidence? J. natn. Cancer Inst. 85, 1554–1557 (1993).
Thor, A.D. et al. Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J. natn. Cancer Inst. 84, 845–855 (1992).
Elledge, R.M. et al. Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res. Treatment 26, 225–235 (1993).
Thorlacius, S., Börresen, A.L. & Eyfjörd, J.E. Somatic p53 mutations in human breast carcinomas in an Icelandic population: A prognostic factor. Cancer Res. 53, 1637–1641 (1993).
Bartek, J., Iggo, R., Gannon, J. & Lane, D.P. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 5, 893–899 (1990).
Banks, L., Matlashewski, G. & Crawford, L. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur. J. Biochem. 159, 529–534 (1986).
Cattoretti, G., Rilke, F., Andreola, S., D'Amato, L. & Delia, D. p53 expression in breast cancer. Int. J. Cancer 41, 178–183 (1988).
Bartek, J. et al. Patterns of expression of the p53 tumor suppressor in human breast tissues and tumors in situ and in vitro. Int. J. Cancer 46, 839–844 (1990).
Davidoff, A.M. et al. Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery 110, 259–264 (1991).
Ostrowski, J.L. et al. p53 expression in human breast cancer related to survival and prognostic factors: An immunohistochemical study. J. Pathol. 164, 75–81 (1991).
Cho, Y., Gorina, S., Jeffery, P.D. & Pavletich, N.P. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265, 346–355 (1994).
Lowe, S.W., Ruley, H.E., Jacks, T. & Housman, D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957–967 (1993).
Fujiwara, T. et al. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 54, 2287–2291 (1994).
Wilson, A.C., Singh, M. & Thompson, H.J. Morphological responses of MOD cells to tamoxifen suggests induction of apoptosis. Proc. Annu. Meet. Am. Assoc. Cancer Res. abstract 903 (1992).
Lim, J.S., Ly, A., Bhimani, R., Frenkel, K. & Troll, W. The chemopreventive agent tamoxifen causes apoptosis. Proc. Annu. Meet. Am. Assoc. Cancer Res. abstract 3693 (1994).
O'Connor, P.M. et al. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res. 53, 4776–4780 (1993).
Lowe, S.W. et al. p53 status and the efficacy of cancer therapy. Science 266, 807–810 (1994).
Ory, K., Legros, Y., Auguin, C. & Soussi, T. Analysis of the most representative tumor-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J. 13, 3496–3504 (1994).
Liljegren, G. et al. Sector resection with or without postoperative radiotherapy for stage I breast cancer; five year results of a randomized trial. J. natn. Cancer Inst. 86, 717–722 (1994).
Ståhl, S., Hultman, T., Olsson, A., Moks, T. & Uhlén, M. Solid phase DNA sequencing using the biotin-avidin system. Nucl. Acids Res. 16, 3025–3038 (1988).
Lagerkvist, A., Stewart, J., Lagerström-Fermér, M. & Landegren, U. Manifold sequencing: Efficient processing of large sets of sequencing reactions. Proc. natn. Acad. Sci. U.SA. 91, 2245–2249 (1994).
Cox, D.R. Regression models and life-tables (with discussion). J. Royal Stat. Soc. B 34, 187–220 (1972).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bergh, J., Norberg, T., Sjögren, S. et al. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1, 1029–1034 (1995). https://doi.org/10.1038/nm1095-1029
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm1095-1029
This article is cited by
High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function
Breast Cancer Research and Treatment (2017)
p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer
Breast Cancer Research (2016)
Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells
Oncogene (2014)
Establishment and characterization of a lung cancer cell line, SMC-L001, from a lung adenocarcinoma
In Vitro Cellular & Developmental Biology - Animal (2014)
Mutant p53 drives invasion in breast tumors through up-regulation of miR-155
Oncogene (2013)